240 related articles for article (PubMed ID: 17485745)
1. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis.
Garrison LP; Towse A; Bresnahan BW
Health Aff (Millwood); 2007; 26(3):684-95. PubMed ID: 17485745
[TBL] [Abstract][Full Text] [Related]
2. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
3. Assessing potential risks and evaluating expected benefits.
Shaya FT; Gu A
Manag Care Interface; 2005 May; 18(5):27-30. PubMed ID: 15941187
[TBL] [Abstract][Full Text] [Related]
4. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.
Bottomley A; Jones D; Claassens L
Eur J Cancer; 2009 Feb; 45(3):347-53. PubMed ID: 19013787
[TBL] [Abstract][Full Text] [Related]
6. Food and Drug Administration approval process for ophthalmic drugs in the US.
Lloyd R; Harris J; Wadhwa S; Chambers W
Curr Opin Ophthalmol; 2008 May; 19(3):190-4. PubMed ID: 18408492
[TBL] [Abstract][Full Text] [Related]
7. A dual track system to give more-rapid access to new drugs: applying a systems mindset to the US food and drug administration (FDA).
Madden BJ
Med Hypotheses; 2009 Feb; 72(2):116-20. PubMed ID: 19036524
[TBL] [Abstract][Full Text] [Related]
8. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group.
Guo JJ; Pandey S; Doyle J; Bian B; Lis Y; Raisch DW
Value Health; 2010 Aug; 13(5):657-66. PubMed ID: 20412543
[TBL] [Abstract][Full Text] [Related]
9. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
10. The identification of benefit in medical intervention: an overview and suggestions for process.
Stang PE; Pham SV; Kinchen K; Raff SB; Mussen F; Gondek K
Am J Ther; 2008; 15(5):495-503. PubMed ID: 18806527
[TBL] [Abstract][Full Text] [Related]
11. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
12. The Food and Drug Administration advisory committees and panels: how they are applied to the drug regulatory process.
Ciociola AA; Karlstadt RG; Pambianco DJ; Woods KL; Ehrenpreis ED;
Am J Gastroenterol; 2014 Oct; 109(10):1508-12. PubMed ID: 25001252
[TBL] [Abstract][Full Text] [Related]
13. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
Wright C; Schnoll S; Bernstein D
Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
[TBL] [Abstract][Full Text] [Related]
15. Changing end points in breast-cancer drug approval--the Avastin story.
D'Agostino RB
N Engl J Med; 2011 Jul; 365(2):e2. PubMed ID: 21707384
[No Abstract] [Full Text] [Related]
16. Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products.
Rock EP; Scott JA; Kennedy DL; Sridhara R; Pazdur R; Burke LB
J Natl Cancer Inst Monogr; 2007; (37):27-30. PubMed ID: 17951228
[TBL] [Abstract][Full Text] [Related]
17. New office and new leader aim to streamline FDA cancer drug review process.
Twombly R
J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
[No Abstract] [Full Text] [Related]
18. Advisory committees at FDA: the Hinchey Amendment and "conflict of interest" waivers.
Lietzan E
J Health Law; 2006; 39(4):415-49. PubMed ID: 17402656
[TBL] [Abstract][Full Text] [Related]
19. Nutraceuticals: miracle or meme?
Ridinger MH
Clin Pharmacol Ther; 2007 Oct; 82(4):352-6. PubMed ID: 17851571
[TBL] [Abstract][Full Text] [Related]
20. Original research: Intravenous ribavirin--review of the FDA's Emergency Investigational New Drug Database (1997-2008) and literature review.
Riner A; Chan-Tack KM; Murray JS
Postgrad Med; 2009 May; 121(3):139-46. PubMed ID: 19491552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
